Hexyon

Hexyon is an injectable vaccine containing Haemophilus influenzae type b polysaccharide, diphtheria toxoid, tetanus toxoid, pertussis antigens, inactivated poliovirus and hepatitis B surface antigen. Formulated as a sterile liquid for intramuscular administration, the preparation is marketed in the European Union for use in pediatric and adolescent immunization schedules. It is a prescription‑only product designed to stimulate active immunity against multiple bacterial and viral diseases through protective antibody responses.

Hexyon is indicated for active immunization against several infectious diseases in children and adolescents according to recommended vaccination schedules. - Diphtheria, providing protection against Corynebacterium diphtheriae toxin in infants and children. - Tetanus, inducing immunity to tetanus neurotoxin after primary series. - Pertussis (whooping cough), targeting Bordetella pertussis antigens to reduce severe cough episodes. - Poliomyelitis, preventing disease caused by poliovirus types 1, 2 and 3 in children. - Haemophilus influenzae type b infection, reducing risk of invasive H. influenzae disease, especially meningitis. - Hepatitis B, stimulating antibodies to hepatitis B surface antigen for long‑term protection.

Hexyon may cause local and systemic reactions, most of which are mild and transient.

Common: - Pain, redness or swelling at the injection site, typically lasting one to two days. - Low‑grade fever (usually ≤38.5 °C) occurring within 24 hours after vaccination. - Irritability or fussiness in infants and young children, often accompanied by mild sleep disturbance. - Mild headache or reduced appetite that resolves without medical intervention.

Serious: - Severe allergic reaction, including anaphylaxis, characterized by hives, difficulty breathing, or swelling of the face and throat. - High fever (≥40 °C) or seizures occurring shortly after the dose, requiring prompt evaluation. - Prolonged crying lasting more than three hours or signs of hypotension such as pale skin and lethargy.

Before administering Hexyon, healthcare providers should assess the patient’s health status and vaccination history to minimize risks. - Do not give Hexyon to anyone with a severe allergy to any vaccine component, such as latex or yeast proteins. - Postpone vaccination if the person has a moderate or severe acute illness (e.g., fever, respiratory infection) until recovery. - Use caution in immunocompromised patients, as they may mount a reduced immune response. - Safety during pregnancy is not established; defer use unless the benefit outweighs potential risk. - Confirm the recipient meets the age and schedule requirements for the vaccine series. - Observe the patient for at least 15 minutes after injection to identify immediate reactions.

Hexyon may interact with other vaccines or medications, and certain conditions require special consideration.

Avoid: - Simultaneous administration of Hexyon with live attenuated viral vaccines (e.g., measles‑mumps‑rubella) without an appropriate interval. - Concomitant use of high‑dose immunoglobulin or blood products that could neutralize vaccine antigens. - Administration during acute severe allergic reactions to other agents.

Use with caution: - Patients receiving immunosuppressive therapy, as the vaccine response may be diminished. - Individuals taking antipyretic or analgesic medications, which can mask fever after vaccination. - Persons with a history of seizures, who may need closer monitoring after immunization.